Alzheimer Disease Vaccine

Alzheimer epitope vaccine induces strong Th2-type anti-A-beta antibody response

Published in Vaccine Weekly, May 24th, 2006

A prototype Alzheimer disease epitope vaccine induced strong Th2-type anti-A-beta antibody response with Alum to Quil A adjuvant switch

According to recent research published in the journal Vaccine, "Beta-amyloid (A-beta) peptide has been proposed to be a causal factor in Alzheimer disease (AD). Currently being investigated, active and passive A-beta-immunotherapy significantly reduce AD plaque deposition, neuritic dystrophy, and astrogliosis in the brains of APP transgenic (APP/Tg) mice. Immunization with A-beta₄₂ formulated in the Th1-type adjuvant QS21 was beneficial for AD patients with significant titers of anti-A-beta antibodies, however, 6% of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2006-05-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry